ReviewFrontiers in immunology2026
Anti-DPPX antibody-associated encephalitis with the first detected anti-Yo antibody during one-year follow-up: a case report.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-dipeptidyl-peptidase-like protein 6 (DPPX) antibody encephalitis is an ultra-rare subtype of autoimmune encephalitis (AE), with no more than 115 cases reported in the literature to date. Anti-Yo antibody-associated encephalitis is also uncommon. No previous case reports have described anti-DPPX antibody-associated encephalitis with anti-Yo antibody first detected during the one-year follow-up. This article presents the first such case, admitted to the Department of Neurology, the Affiliated Traditional Chinese Medicine Hospital, Guangzhou Medical University. The patient presented with acute onset manifested by increased muscle tone, neuronal hyperexcitability, autonomic dysfunction and transient myocardial injury. Anti-DPPX antibodies were detected in both serum and cerebrospinal fluid (CSF) upon initial admission, while anti-Yo antibodies were first detected during one-year follow-up. The patient achieved remarkable clinical remission after receiving immunotherapy with intravenous immunoglobulin (IVIG) combined with corticosteroids. We comprehensively summarize the clinical manifestations, diagnostic workup, therapeutic regimen and long-term follow-up outcomes of this case, and conduct a review of the available literature to investigate the pathophysiological mechanisms underlying these two antibodies. This report aims to raise clinicians' awareness of rare subtypes of AE, provide effective treatment strategies, and advance the understanding of the heterogeneous spectrum of AE.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.